Celebrating 20 Years of IP Excellence

Characters are pulling a rope written PATENT on top as this article is about Indian Patent Law Basics

Amendments to a PCT Application under Article 19 and Article 34

In an event where an applicant wishes to make certain changes in only the claims of a direct PCT application, the applicant can invoke the procedure under Article 19. The applicant can only amend the claims under Article 19. The applicant cannot amend the description or the  drawings. There are certain conditions for filing an amendment under this Article. The application must be filed within 2 months from the issuance of the International Search Report and no new matter can…

Read more

Sipping on IP – Conversation on Intellectual Property x

Sipping on IP – Conversation on Intellectual Property

Well I am guessing the title of this post may have piqued your interest. ‘Sipping on IP’ is an initiative taken by BananaIP Counsels, where everyone gathers over coffee and lets ideas, discussions and conversations about intellectual property brew. There are no ground rules and the conversation can be about varied topics from more current pressing issues to any IP related concept. It is a great way to connect, take a break and learn from your peers. Let’s see what we…

Read more

Intellepedia - IP News Updates

Patent Law in India- PPT on Patentability Requirements by Dr. Kalyan C. Kankanala at NLSIU

This presentation was delivered by Dr. Kalyan C. Kankanala at NLSIU, Bangalore, India, as a part of the Patent law course offered for PGDIP students. The presentation covers: Introduction to Patentability Requirements and their role in the Patent System in India; The Patent Filter Model; Patentable Subject Matter - Eligible Subjects and Ineligible Subjects; Inventions and Non-Patentable Subject Matter; Section 3 Exclusions with special reference to Section 3(d); Novartis Case - New Form, Known…

Read more

pharmaceutical patent x

Merck v. Glenmark – A Bitter Battle of Pills

  The Delhi High Court has restrained Glenmark from making and marketing generic versions of Merck Sharp & Dohme (MSD)'s popular antidiabetic drug “Januvia” (sitagliptin) and “Janumet” (combination of sitagliptin and metformin) in its latest order dated October 7, 2015. The order restrains Glenmark from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate or any other salt of Sitagliptin in any form, alone or in combination with one or more other drugs or from…

Read more